72 related articles for article (PubMed ID: 10800497)
1. Breast cancer.
Buzdar AU; Hortobagyi GN
Cancer Chemother Biol Response Modif; 1999; 18():435-69. PubMed ID: 10800497
[No Abstract] [Full Text] [Related]
2. Re: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
Mehta RS; Schubbert T
J Natl Cancer Inst; 2008 May; 100(9):680; author reply 680-1. PubMed ID: 18445822
[No Abstract] [Full Text] [Related]
3. Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer?
Hu JC; Mokbel K
Eur J Surg Oncol; 2001 Jun; 27(4):335-7. PubMed ID: 11417974
[No Abstract] [Full Text] [Related]
4. Reassessing tumor markers in local recurrences of breast cancer: a new insight.
Pedrini JL; Pedrini M; Savaris RF; Machado L; Grudzinski M; Zettler CG
Med Sci Monit; 2004 Dec; 10(12):BR462-7. PubMed ID: 15567977
[TBL] [Abstract][Full Text] [Related]
5. Introduction. Local management of early-stage breast cancer.
Pierce LJ
Semin Radiat Oncol; 2011 Jan; 21(1):1-2. PubMed ID: 21134647
[No Abstract] [Full Text] [Related]
6. Molecular and genetic markers in the local-regional management of breast cancer.
Haffty BG
Semin Radiat Oncol; 2002 Oct; 12(4):329-40. PubMed ID: 12382191
[TBL] [Abstract][Full Text] [Related]
7. [High-dose chemotherapy with hematopoietic stem-cell support in breast cancer].
Viens P; Maraninchi D
Bull Cancer; 2001 Sep; 88(9):835-41. PubMed ID: 11604355
[No Abstract] [Full Text] [Related]
8. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
[TBL] [Abstract][Full Text] [Related]
10. The impact of HER-2 status on local recurrence in women with stage I-II breast cancer treated with breast-conserving therapy.
Harris EE; Hwang WT; Lee EA; Cengel KA; Feldman MD; Demichele A; Kao G; Solin LJ
Breast J; 2006; 12(5):431-6. PubMed ID: 16958961
[TBL] [Abstract][Full Text] [Related]
11. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
[TBL] [Abstract][Full Text] [Related]
12. Anthracycline therapy may be avoidable in early breast cancer, new studies suggest.
Tuma R
J Natl Cancer Inst; 2008 Apr; 100(7):459-61. PubMed ID: 18364497
[No Abstract] [Full Text] [Related]
13. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for metastatic breast cancer: a therapy whose time has passed.
Vogl DT; Stadtmauer EA
Bone Marrow Transplant; 2006 Jun; 37(11):985-7. PubMed ID: 16708060
[No Abstract] [Full Text] [Related]
14. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
[TBL] [Abstract][Full Text] [Related]
15. The predictive role of HER2 overexpression in early breast cancer.
Tartarone A; Romano G; Iodice G; Capobianco A; Di Renzo N
J Clin Oncol; 2003 Aug; 21(16):3179-80; author reply 3180. PubMed ID: 12915616
[No Abstract] [Full Text] [Related]
16. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation.
Kim YS; Konoplev SN; Montemurro F; Hoy E; Smith TL; Rondón G; Champlin RE; Sahin AA; Ueno NT
Clin Cancer Res; 2001 Dec; 7(12):4008-12. PubMed ID: 11751494
[TBL] [Abstract][Full Text] [Related]
17. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
Li X; Lewis MT; Huang J; Gutierrez C; Osborne CK; Wu MF; Hilsenbeck SG; Pavlick A; Zhang X; Chamness GC; Wong H; Rosen J; Chang JC
J Natl Cancer Inst; 2008 May; 100(9):672-9. PubMed ID: 18445819
[TBL] [Abstract][Full Text] [Related]
18. Human epidermal growth factor receptor 2 testing in breast cancer.
Vang Nielsen K; Jørgensen JT; Schønau A; Øster A
J Clin Oncol; 2007 Sep; 25(25):4020; author reply 4021-3. PubMed ID: 17761991
[No Abstract] [Full Text] [Related]
19. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
[TBL] [Abstract][Full Text] [Related]
20. Anthracyclines in the treatment of HER2-negative breast cancer.
Paik S; Taniyama Y; Geyer CE
J Natl Cancer Inst; 2008 Jan; 100(1):2-4. PubMed ID: 18159066
[No Abstract] [Full Text] [Related]
[Next] [New Search]
